Rallying Around a Disruptive Threat

Continue reading

Enter your email to access this article and all future S2A insights.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Never let a good crisis go to waste can be a useful adage.

How do you apply it when facing a challenge that represents a disruptive threat to how work has always been done?

Early in my career, I participated in an example that has stuck with me.  For R&D and IT in the pharmaceutical industry, the rise of precision medicine was a game changer.  

At the time, the IT function also faced a serious budget cliff.   For the previous few years, it relied heavily on M&A integration funding that was soon to expire.  A reset under new leadership was looming.  

This presented a natural question of how to play the hand.

The default with technology plays to fears that if you don’t invest now, you’ll get left behind.

This time leaders chose a different path that significantly broadened engagement around understanding the challenge and implications for the role of the function.

‍

Before precision medicine technologies began to mature, data reuse was an afterthought.  

While some insights might be drawn from failed trials, the system was designed around making the current submission package as strong as possible in hopes of gaining FDA approval.

‍

While that remains true, the technologies that enable precision medicine triggered a major shift in approach.  Advances in genetics revealed a common reason clinical trials can wash out in the most expensive later stages is that a treatment turns out to be effective in some subsets of the population and not others.  Technology opened the door to distinguishing between those populations.

‍

This has significant economic implications.  Gain the ability to isolate the population where the treatment is safe and effective, rerun trials with that population and a significant proportion of sunk costs in R&D can be recovered.  These technologies also accelerated an ongoing shift towards reducing R&D costs through simulations.  Simulations are only as good as the data behind them.  And data are only as good as what the right people can find in a timely manner. 

Therein lay the crux of the problem.  Any outside consultant would tell you the company was sitting on a gold mine.  Yet realizing the potential would require redesigning the human and technological infrastructure to support data reuse.  In an industry as complex as pharma R&D that is a beast.  

To their credit, instead of throwing around jargon, IT leaders embraced the challenge of ferreting out implications.   Learning that more than two-thirds of researchers considered finding the right data difficult validated the problem.  They also learned their current investments were doing little to help.  By a more than 3 to 1 margin, respondents said they found ad hoc conversations with colleagues more useful for finding the right data than any of the IT systems or business partners.

Mapping connections between sources recognized as the most useful sources gave them a current state picture.  It resembled a scattering of islands accompanied by one long snake.  If anyone had set out to design a less efficient structure to support the direction in which work was evolving, they would have been hard pressed to do so.

That structure was nobody’s fault.  It had arisen organically. It worked fine under earlier conditions, so nobody noticed.  However, it posed a serious liability for where things were going.  

What leaders did next in resisting the pressure to immediately jump in with a solution was key. Instead, they used what they’d learned to engage people on the technological front lines.  Reaching out and weaving it together to paint a clear picture takes an intentional process and time.   They made the investment.  The result of bringing the most relevant knowledge to the table was a solid diagnosis along with scenarios that provided a foundation for developing guiding principles and coordinated actions. 

The moment of truth arrived in the first meeting between top IT and R&D executives.

The candid response that came back was “for the first time, we really understand what you all do!”  

‍

Good strategy reflects the response to a challenge.  When decision makers lack the context for understanding the challenge, bad strategy tends to follow.  

Instead, both sides could now see the primary issues clearly enough that they could work out guiding policies and actions based on actual conditions instead of overly hopeful or fearful assumptions.   

The process had also engaged front line technology leaders in thinking through implications.  That perspective served them well for adapting to shifts in priorities.

Challenging financial and organizational issues still had to be worked through.  What changed reflected the confidence and motivation that came from involving people when their efforts could still make a difference as opposed to inflicting consequences of untested assumptions on them later.

Never let a good crisis go to waste can be a helpful mantra for companies facing disruptive threats.  The key lies in how you decide to put the challenge to good use.

‍

Read More

You May Also Be Interested In:

Bradley Brezinski

What BlackBerry Forgot to Take Apart

Nat Bulkey

Implications for developing better strategy

Heading